Navigation Links
Micromet Announces Changes in Management Team
Date:12/14/2007

1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293, which is currently being tested in a phase 1 clinical trial, is licensed to TRACON Pharmaceuticals, Inc. and is being developed for the treatment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the ri
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO, ... from Mylan NV ("Mylan") (NASDAQ: MYL ) to ... $60.00 per share in cash and 2.2 Mylan ordinary ... The Board previously concluded that Mylan,s unsolicited ... and its future growth prospects and was not in ...
(Date:4/24/2015)... -- Bayer Corporation hosted its annual "Take Your Child to Work ... headquarters.  This is Bayer,s second "Take Your Child To Work ... campus, and Thursday,s event welcomed 230 children ready to see ... Fortunately, for the kids, this was not just another ... "Science For A Better Life," Bayer made sure that "Take ...
(Date:4/24/2015)... , April 24, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, announced the Company will ... Tuesday, April 28, 2015 to discuss the 1st quarter ... listen to the call by dialing 1-888-346-3479. International participants ... should ask to be joined into the IGI Laboratories, ...
Breaking Medicine Technology:Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4Bayer Hosts "Take Your Child to Work Day" 2Bayer Hosts "Take Your Child to Work Day" 3Bayer Hosts "Take Your Child to Work Day" 4
... Calif., March 31, 2011 NewCardio, Inc., (OTC Bulletin ... developer, announced today that the Company has been invited ... performance study at an upcoming conference entitled "Cardiovascular Safety ... Food and Drug Administration (FDA), the Cardiac Safety Research ...
... 31, 2011 The U.S. Department of Energy has ... field of medical technology and innovation for commercializing the ... agency, Dilon and similar entrepreneurs, "build the new industries ... our toughest global challenges." The Dilon 6800® ...
Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6U.S. Department of Energy Hails Dilon Diagnostics as a Medical Technology Pioneer and Top National Innovator 2
(Date:4/27/2015)... (PRWEB) April 27, 2015 Winscribe ... to their suite of mobile speech productivity technology, ... iOS tablets and smartphones. , Winscribe ... Operating System since 2005. With the latest ... fourth generation mobile application interface in the last ...
(Date:4/27/2015)... Pure n Natural Systems, Inc. is pleased to ... at http://www.purennatural.com/ . The new website includes ... featured and sale items, as well as the official ... n Natural Systems’ website is designed to give customers ... neatly organized and provides plenty of useful information to ...
(Date:4/27/2015)... Aliso Viejo, CA (PRWEB) April 27, 2015 ... directly on top of footage with ProTelestrator from Pixel Film ... to draw a freehand sketch over a moving or still ... broadcasts to diagram and analyze sports plays or incoming weather ... "Animate Mode" checkbox and then adjust the frame slider to ...
(Date:4/27/2015)... Cambia Health Solutions is pleased to ... as Operating Partner within its Direct Health Solutions ... building companies that change the way people experience the ... be responsible for accelerating Cambia’s investments, which are focused ... economically sustainable and person-focused, while looking for new strategic ...
(Date:4/27/2015)... April 27, 2015 Doping has been ... Armstrong and Alex Rodriguez continue to capture the public’s ... a new frontier in performance enhancement along with new ... TV , accomplished neuroscientist Anjan Chatterjee of ... the ethics and dangers of these enhancements in sports. ...
Breaking Medicine News(10 mins):Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 2Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 3Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 4Health News:Pure n Natural Systems, Inc. Launches New Website Design 2Health News:Pure n Natural Systems, Inc. Launches New Website Design 3Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2Health News:Cambia Welcomes Ben Albert as Operating Partner 2Health News:Cambia Welcomes Ben Albert as Operating Partner 3Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 3
... Study says surgical advances may explain away the link ... News) -- Cataract surgery doesn,t hasten vision loss in ... conclusion of a new study that challenges the findings ... between cataract surgery and accelerated AMD progression. , AMD ...
... mouse model of human leukemia has provided critical insight into ... myeloid leukemia stem cells. The study, published by Cell Press ... Stem Cell , is likely to have a profound impact ... stem cells. , Leukemia stem cells (LSCs) were initially described ...
... Patient Advocate Foundation (NPAF) -- a national, non-profit organization ... patient access to health care through public policy reform ... Congress for passing and President Obama for signing the ... extend health coverage to four million uninsured American children. ...
... disease, A Su Salud revealed high incidence of diabetes, ... $55 million in free and low cost medical services ... -- CVS/pharmacy, the nation,s leading retail ... Salud" (To Your Health) health fairs, providing free health ...
... Montreal, Canada February 05, 2009 A ... who have received kidney transplants and compares them ... a significantly higher prevalence of psychiatric conditions (depression, ... adolescents who had undergone a transplant. The study ...
... recent survey of in-house,physician recruiters across the country ... on hospital systems throughout the United States, and,recruiting ... the lack,of physicians to fill key provider roles. ... from their most recent recruitment,and retention survey of ...
Cached Medicine News:Health News:Cataract Surgery Doesn't Worsen AMD 2Health News:Leukemia stem cells have more in common with embryonic stem cells than adult stem cells 2Health News:National Patient Advocate Foundation Applauds Congress' and President Obama's Decision to Extend Health Coverage to Four Million Uninsured Children 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 3Health News:Psychological impact found in adolescents with kidney transplants 2Health News:PracticeMatch: Healthcare Survey Defines Physician Recruitment Challenges 2
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm slit. Blade tip dimension: 14.1 mm x 2.85 mm x 3.3 mm....
Full Handle Laseredge Slit Blade Knife, 2.65 mm angled double bevel. Blade tip dimension: N/A x 2.65 mm x N/A....
Full Handle Laseredge Slit Blade Knife, 2.65 mm angled bevel up. Blade tip dimension: 14.4 mm x 2.65 mm x 3.7 mm....
Medicine Products: